News

Ardelyx (NASDAQ:ARDX) expects to generate close to $500 million in revenue this year and reach profitability in 2027, supported by continued growth of its IBS-C treatment IBSRELA and hyperphosphatemia treatment XPHOZAH, executives said at a Morgan Stanley event. Chief Executive Officer Mike Raab sa

Record revenue masks payer headwinds forcing IBSRELA guidance cuts.

In August 2026, Ardelyx, Inc. reported second-quarter 2026 results showing revenue of US$120.88 million versus US$97.66 million a year earlier, with net loss narrowing to US$16.72 million and basic loss per share improving to US$0.07 from US$0.08. Alongside its results, Ardelyx updated full-year 2026 guidance, lifting expected IBSRELA revenue to US$350 million–US$370 million while keeping XPHOZAH revenue guidance steady at US$110 million–US$120 million, giving investors a clearer view of how...

Ardelyx (ARDX) is back in focus after reporting record Q2 2026 revenue driven by IBSRELA and XPHOZAH, while missing earnings estimates and trimming IBSRELA guidance because of payer related hurdles. See our latest analysis for Ardelyx. Despite the record Q2 revenue, Ardelyx’s recent earnings miss and reduced IBSRELA guidance appear to be weighing on sentiment, with the share price down 9.48% over 30 days and 20.81% year to date, even though the 5 year total shareholder return of 220.39%...

Ardelyx Inc (ARDX) delivers 31% revenue growth in Q2 2026 while navigating payer-imposed challenges that led to a lowered Ibsrela outlook and withdrawal of Xphozah guidance.

Ardelyx (ARDX) delivered earnings and revenue surprises of -40.00% and -2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Ardelyx (NASDAQ:ARDX) reported second-quarter product revenue of $118 million, up 31% from a year earlier and representing the company’s largest quarterly revenue total to date. The company lowered its 2026 revenue outlook for IBSRELA while maintaining its forecast for XPHOZAH, citing increased paye

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx, Inc (NASDAQ:ARDX) is a biotech company. It makes drugs for gut and kidney conditions. Its main drug is Ibsrela, a treatment for IBS with constipation, and its second drug is Xphozah, which lowers phosphate levels in dialysis patients. Claude is bullish on the stock because the price has not caught up to the company’s […]

Aquestive Therapeutics (AQST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

This biotech specializing in gastrointestinal and cardiorenal therapies reported a notable insider sale following strong 1-year returns.

Ardelyx, Inc. (NASDAQ:ARDX) is among the best low priced stocks to get rich in 2026. On June 16, Ladenburg started coverage on Ardelyx, Inc. (NASDAQ:ARDX) with a Buy rating and a price target of $16. According to TheFly, the company is currently focused on expanding demand for Ibsrela, sustaining sales momentum for Xphozah, growing its […]

Ardelyx stock snapshot and recent performance Ardelyx (ARDX) has been drawing more attention after recent share price moves, with the stock up 3.2% over the past day and 7.2% over the past week, despite being down 12.4% over the past month. See our latest analysis for Ardelyx. Recent trading has been choppy, with the share price sliding over the past month but roughly flat over the past quarter, while the 1 year total shareholder return of 55.7% reflects a much stronger longer term...

Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to invest in its pipeline and positioning the business for sustainable profitability. Chief Financia

CFO said at a conference that profitability is “right around the corner,” though the company is waiting for more top-line certainty before formal guidance.

In early May 2026, Ardelyx presented a new long-term analysis at the National Kidney Foundation meetings showing that XPHOZAH (tenapanor) reduced serum phosphate in chronic kidney disease patients on dialysis without clinically meaningful changes in other electrolytes, nutrition markers, body mass, or blood pressure, reinforcing its safety profile as an add-on therapy. The extended NORMALIZE and OPTIMIZE data, together with Ardelyx’s peer exchange on XPHOZAH’s first-in-class mechanism,...

Ardelyx (ARDX) reported first quarter 2026 results, with revenue of US$94.47 million and a net loss of US$37.61 million, and reiterated full-year revenue guidance for IBSRELA and XPHOZAH. See our latest analysis for Ardelyx. Ardelyx’s latest earnings release and guidance update come after a strong 1 year total shareholder return of 91.89%, while the 30 day share price return of 18.93% suggests momentum has picked up again around US$7.10. If this earnings driven move has you looking beyond...

It's been a pretty great week for Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders, with its shares surging 16% to US$6.88 in...

Ardelyx Inc (ARDX) reports significant revenue increases for IBSRELA and XPHOZAH, while navigating operational challenges and investing in future growth.

Moby summary of Ardelyx, Inc.'s Q1 2026 earnings call

Michael Raab: Thank you. At Ardelyx, we are building an innovative pipeline of medicines for patients with unmet medical needs. As we build on this momentum, our focus is on executing on our four key priorities: accelerating the growth of Ibsrela, maintaining the Exposa momentum, building and expanding our pipeline, and delivering strong financial results.

Ardelyx (NASDAQ:ARDX) executives said the company entered 2026 with “another significant year of growth” underway, highlighting strong first-quarter demand for its IBS-C product IBSRELA and continued momentum for kidney disease drug XPHOZAH, while also advancing pipeline efforts aimed at expanding t

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

If you are wondering whether Ardelyx at around US$5.95 is offering good value or asking too much, you are not alone. This article is built to help you frame that question clearly. The stock has seen mixed recent returns, with a 7.8% decline over the last 7 days, a 5.5% gain over 30 days, a 3.3% decline year to date, and a 13.1% return over the past year, which can change how you think about both risk and opportunity. Recent attention on Ardelyx has focused on how its pipeline, regulatory...

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wondering if Ardelyx at around US$5.94 is offering real value or just headline noise? This article walks you through what the numbers are actually saying about the stock. The share price return sits at 8.4% over the last 7 days. The 30-day and year-to-date returns are a 5.3% decline and a 3.4% decline respectively, set against a 30.5% gain over the past year and a 35.0% return over 3 years, with a 20.2% decline across 5 years. Recent moves come against a backdrop of ongoing interest in...